Después de casi 14 años en Hospital la Salud ha llegado el momento de cerrar una etapa muy especial. Durante este tiempo, he tenido la oportunidad de crecer tanto personal como profesionalmente, y espero haber dado siempre lo mejor de mí, con el foco en lo más importante: los pacientes. Quiero agradecer de corazón a todo el equipo de esta gran “casa” por tantos años de aprendizaje, compañerismo y experiencias inolvidables. Estoy seguro de que nuestros caminos volverán a cruzarse. Ahora nos esperan nuevos retos y aventuras que afronto con entusiasmo y un gran equipo Un abrazo a todos y hasta pronto. #Feliz2025

🚨 Hypertension remains the #1 cause of death worldwide! 🌍💔 But new drugs are changing the game. 🔬 Aprocitentan, a dual endothelin receptor antagonist, is the first new #hypertension drug class approved in almost 2 decades! 💊🚀 📉 New therapies like siRNAs, aldosterone synthase inhibitors & non-steroidal MRAs could transform #BloodPressure management. 💡 Personalized medicine & better adherence strategies will be key! 🔑 🔗 Read more: #Cardiology #HeartHealth #MedicalInnovation #HypertensionAwareness #BloodPressureMatters ❤️🩺

🫀 Beyond Medications: Nonpharmacologic Care in Heart Failure 🏃‍♂️🥗💤 A new review highlights key lifestyle strategies to optimize HF management: 🔹 Diet & Nutrition: DASH/Mediterranean diets, tailored sodium & fluid intake 🥦🍊 #HeartHealth 🔹 Exercise & Cardiac Rehab: Reduces symptoms, improves QoL & survival 🏋️‍♂️🚶 #ExerciseIsMedicine 🔹 Sleep & Mental Health: Addressing apnea & mood disorders for better HF outcomes 😴🧠 #SleepMatters 🔹 Substance Use: Managing alcohol, tobacco & drugs to protect the heart 🚭🚫 #HeartFailure 📢 Multimodal, evidence-based approaches can transform HF care! #CardioTwitter #HeartFailure #LifestyleMedicine

🚨 Semaglutide improves heart health post-CABG! 📊 In patients with obesity & prior bypass surgery: 🔻 28% ↓ major cardiovascular events (MACE) 🔻 36% ↓ heart failure hospitalizations 🔻 54% ↓ risk of nonfatal heart attacks 💉 A game-changer for secondary prevention! #Cardiology #HeartHealth #CABG #Semaglutide #Obesity #GLP1 #SELECT trial 📁

🚨 Too much sitting increases heart risk! 📉 >10.6h/day of sedentary behavior = ⚠️ 40% ↑ risk of heart failure ⚠️ 54% ↑ risk of CV mortality 🏃‍♂️ Even physically active individuals are affected! 🔁 Swap sitting for movement to cut risks. #Cardiology #HeartHealth #SedentaryLifestyle #research

Anaemia, neurohormonal activation, and myocardial iron depletion in heart failure: can this vicious circle be broken? #EMPATROPISM-FE trial 🔬 New study in #HFrEF: Anemia predicts iron homeostasis dysregulation and modulates response to empagliflozin 🏥. 📉 Anemic patients show lower myocardial iron content, worse LV function, and higher norepinephrine levels 📈 Empagliflozin increases myocardial iron, improves exercise capacity, and reduces sympathetic activation 🩸 Sympatholysis may explain the cardiac & systemic benefits of #SGLT2i 🔗 Read more: #Cardiology #HeartFailure

RT @mvaduganathan: 🔥#CONFIDENCE, the largest trial of combination #SGLT2i + #MRA (versus either alone) in #CKD and #T2D, is fully recruited…

🚨 New Insights on HFpEF & Central Adiposity! 🚨 A recent study in @EurHeartJ reveals a near-universal presence of central adiposity in patients with heart failure with preserved ejection fraction (HFpEF). 📊💔 🔹 Key Findings: ✅ Obesity (BMI ≥30 kg/m²) is common in HFpEF but waist-to-height ratio (WHtR) ≥0.5 is an even stronger predictor of outcomes. ✅ Higher WHtR correlates with increased heart failure 🏥, independent of BMI. 📈 ✅ Women show a steeper risk curve compared to men. 👩⚠️ ✅ Neprilysin inhibition shows consistent effects across BMI and WHtR groups. 🔎 Clinical Takeaways: 1️⃣ BMI alone is not enough—WHtR is a better marker of central adiposity & risk stratification. 2️⃣ Obesity is not just a number but a key HFpEF phenotype requiring tailored interventions. 3️⃣ Addressing visceral fat may improve HFpEF outcomes—time to rethink metabolic strategies in cardiology! 📖 Read more: @ESC_Journals #HFpEF #CardioTwitter #HeartFailure #Obesity #WHtR #MetabolicCardiology

RT @SVCardio: Nuevo número de nuestra revista #latido disponible ❗️ 👉 Monográfico de actualización en cardio-oncología por el grupo de tra…

RT @JuliaSellerm: Top3 heart failure trials in January 2025 🥇🔝 Review HFpEF @NEJM 🥈Diuretic potentiation strategies in acute HF @JACCJou…

RT @cardioteca: ☑️ Cómo el SZC prolongado mejora el manejo de la hiperpotasemia y la terapia con iSRAA 🧑⚕️ Alfonso Valle Muñoz @Va…

🫀 THREAD: Cannabis and Cardiovascular Disease 🫀 As cannabis use skyrockets globally, its potential cardiovascular risks are coming to light. Here are the highlights from the @NatureReviews article “Clearing the Haze” 🧵👇 1/ Cannabis consumption is rising 🌍 With widespread legalization, cannabis use has surged. But what are the risks for our hearts? 💔 Evidence links cannabis to myocardial infarction (MI), arrhythmias, and more. 2/ Endocannabinoid system 🧬 Cannabinoid receptors (CB1, CB2) influence cardiovascular health. ⚠️ CB1 activation: oxidative stress, inflammation, and atherosclerosis. 💡 CB2 activation: potential benefits in vascular inflammation. 3/ Cardiovascular risks Cannabis use is associated with: 💔 Increased risk of MI. ⚡ Arrhythmias and heart failure. ❗ Combining cannabis with tobacco amplifies these risks. 4/ Synthetic cannabinoids = heightened danger ⚠️ Compounds like K2 and Spice are far more toxic than natural cannabis, leading to severe cardiovascular and neuropsychiatric outcomes. 5/ Potential therapies 🔬 CB1 antagonists and CB2 agonists show promise in treating inflammation, obesity, and atherosclerosis. ⚠️ However, clinical applications remain limited. 6/ The bottom line Cannabis is not “harmless.” Its cardiovascular effects require urgent attention as global consumption rises. Public awareness and more research are essential. 📁 #Cardiology #Cannabis #PublicHealth #HeartHealth #Research

Canagliflozin helps ⬇️ the need for increased loop diuretics in HF with type 2 diabetes. 🚑💊 #CANVAS ➕ #CREDENCE trials 🔑 Key insights: 1.Improves diuretic efficiency. 2.Reduces HF hospitalization risk. 3.Supports better fluid management. #HeartFailure #Cardiology #Diabetes #SGLT2Inhibitors #MedicalResearch #HeartHealth 📁

RT @CristobMorales: Semaglutide 2·4 mg improved heart failure-related symptoms and physical limitations, and reduc…

Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With Heart Failure 👉Study Objective: To evaluate Sodium Zirconium Cyclosilicate (SZC) for managing hyperkalemia during spironolactone optimization in patients with heart failure with reduced ejection fraction (HFrEF). 👉Primary Findings: •SZC significantly improved potassium management. •71% of patients on SZC maintained normal potassium levels (3.5–5.0 mEq/L) while on ≥25 mg/day spironolactone, compared to 36% on placebo (OR: 4.45; p < 0.001). 👉Secondary Outcomes: •Reduced time to first hyperkalemia episode (HR: 0.51; p < 0.001). •Fewer dose reductions or discontinuations of spironolactone due to hyperkalemia (HR: 0.37; p=0.006). •SZC maintained spironolactone dosing in 81% of patients vs. 50% with placebo. 👉Safety: •Adverse events were similar between SZC (64%) and placebo (63%). •Slightly higher rates of heart failure events (10% SZC vs. 2% placebo) noted as exploratory. 📌Conclusion: SZC enables safe optimization of spironolactone in HFrEF patients at risk of hyperkalemia, addressing a key barrier to MRA use in clinical practice. @jacc

🔬 Efficacy & Safety of Finerenone in CKD & T2D: Insights from FIDELITY Analysis Key Highlights: 👉 Finerenone Efficacy: Significant reduction in cardiovascular (CV) & kidney outcomes, consistent across diuretic subgroups 👉Safety Profile: Comparable treatment-emergent adverse events (TEAEs) irrespective of diuretic use 👉 Hyperkalaemia: Low incidence of hospitalization or discontinuation due to this side effect. 🟢Finerenone delivers consistent CV & renal benefits in CKD+T2D, unaffected by diuretic use at baseline. #HeartHealth #CardioTwitter #Nephrology #Diabetes #Finerenone #CardiovascularDisease #CKD

Empagliflozin revolutionizes heart failure treatment! 🫀 📖 Unlocking the power of empagliflozin: Rescuing inflammation in hyperglycaemia- exposed human cardiomyocytes through comprehensive multi-level analysis 🔹 ⬇️ inflammation in diabetic & non-diabetic patients. 🔹 Restores cardiomyocyte function under high-glucose stress. 🔹 Enhances mitochondrial efficiency & reduces cell stress. 🔹 Supported by RNA-seq & clinical trial meta-analysis. #Cardiology #HeartHealth #DiabetesCare #Empagliflozin 📁

RT @cardioteca: 🏥¿Cómo el ciclosilicato de zirconio sódico está transformando el manejo de la hiperpotasemia en hospitales? 🧑⚕️ Alfonso V…

🔴“New findings from the FINEARTS-HF trial reveal that finerenone significantly ⬇️ CV☠️ and HF🏥, especially those with recent worsening events!” Key Highlights: 👉Risk Reduction: Finerenone ⬇️ CV☠️ and HF🏥, with the strongest benefits seen in patients treated within 7 days of worsening heart failure (WHF). 👉Safety Profile: Despite targeting high-risk patients, the drug showed no significant increase in adverse events like hyperkalemia or kidney issues. 👉Clinical Implications: Early initiation of finerenone after WHF could improve outcomes for heart failure patients with HFmr/HFpEF #ClinicalResearch #HeartFailure #cardiology #Finerenone 📁@JACCJournals 📌

📢 New insights from #PARAGLIDEHF 👉Sacubitril/valsartan significantly ⬇️ NT-proBNP levels in HFpEF patients (EF>40%) post-worsening HF 👉effective & safe whether patients are ACEi/ARB naïve or not. 🌟 Early initiation = better outcomes. 📁 #HeartFailure #CardiologyResearch

🚨Optimizing HFpEF Outcomes Key highlights from @NEJM’s latest on Heart Failure with Preserved Ejection Fraction (HFpEF): 📊 HFpEF cases on the rise (50% of HF admissions). 💊 Innovations include: •SGLT2 inhibitors for fewer hospitalizations. •GLP-1 agonists enhancing QoL in obese patients. 🎯 Focus remains on symptom relief, not mortality reduction. #Cardiology #HFpEF #MedicalResearch 📁 @chemachir